Table 5.
The graphene oxide (GO)–dextran (Dex) composites, their size, the drug used, the type of cancer cell treated, drug loading, and release efficiency.
| GO–Dextran Nanocomposites | Size | Drug Used | Cancer Cell Line | Drug Loading Efficiency | Drug Release Efficiency | Reference |
|---|---|---|---|---|---|---|
| GO–IONP–CS–Dex | 425.33 ± 3.91 nm | DOX | Human lung cancer cells (A549) | 140.4% | 36.5% at pH 7.4, 59.2% at pH 5.0 | [171] |
| NGO–HDex | 223–239 nm | DOX | Multidrug-resistant breast cancer cells (MCF-7/ADR) | Above 90% | 11% at pH 7.4, 28% at pH 5.5 | [169] |
| rGO/DOX/RGD–Dex | 60 nm | DOX | Murine melanoma cells (B16F10) | 19.75% | 7.4% at pH 7.4, 12.7% at pH 6.8, 38.4% at pH 5.3 | [170] |
| GO–CS/Dex | 373.15 ± 0.67 nm | DOX | Human breast cancer cells (MCF-7) and human liver cancer cells (HepG2) | 63.7% | 28.9% at pH 7, 49.1% at pH 5 |
[124] |
| GO100–Dex | 133 ± 7.18 nm | DOX | human umbilical vein endothelial cells (HUVECs) |
64% | 48% at pH 5.8, 20% at pH 7 |
[172] |